• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comment on: "Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes".

作者信息

Alcántara Montero Antonio

机构信息

Centro de Salud Trujillo, Trujillo, Cáceres, Spain.

出版信息

World J Urol. 2025 Sep 15;43(1):553. doi: 10.1007/s00345-025-05942-5.

DOI:10.1007/s00345-025-05942-5
PMID:40952485
Abstract
摘要

相似文献

1
Comment on: "Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes".关于《维贝格隆治疗膀胱过度活动症：疗效、安全性及患者报告结局的全面综述》的评论
World J Urol. 2025 Sep 15;43(1):553. doi: 10.1007/s00345-025-05942-5.
2
Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes.维贝格隆治疗膀胱过度活动症：疗效、安全性及患者报告结局的全面综述
World J Urol. 2025 Aug 26;43(1):514. doi: 10.1007/s00345-025-05799-8.
3
Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta-analysis.维贝格隆与米拉贝隆治疗膀胱过度活动症的疗效和安全性：一项系统评价和网状Meta分析
Low Urin Tract Symptoms. 2023 May;15(3):80-88. doi: 10.1111/luts.12475. Epub 2023 Mar 2.
4
Satisfaction and persistence with vibegron in the first 6 months of overactive bladder treatment: interim results of the phase 4, real-world COMPOSUR study.膀胱过度活动症治疗前6个月使用维贝格隆的满意度和持续性：4期真实世界COMPOSUR研究的中期结果
BMC Urol. 2025 Apr 2;25(1):66. doi: 10.1186/s12894-025-01742-6.
5
Comparative Efficacy and Safety of Mirabegron and Vibegron in Female Patients With Overactive Bladder: A Systematic Review and Meta-analysis of Randomized Controlled Trials.米拉贝隆与维贝隆治疗女性膀胱过度活动症的疗效和安全性比较：一项随机对照试验的系统评价和荟萃分析
Urology. 2025 May;199:182-190. doi: 10.1016/j.urology.2025.02.018. Epub 2025 Feb 17.
6
Comparative efficacy and adverse effects of β3-agonists and antimuscarinics in overactive bladder: a network and component network meta-analysis.β3 激动剂与抗毒蕈碱药物治疗膀胱过度活动症的疗效及不良反应比较：网状和成分网状荟萃分析
Eur J Clin Pharmacol. 2025 Jun 7. doi: 10.1007/s00228-025-03855-1.
7
Add-on or switch to vibegron in patients with overactive bladder insufficiently responding to initial 4-week antimuscarinics: a randomised, parallel-group, multicentre trial () .对初始4周抗毒蕈碱药物治疗反应不足的膀胱过度活动症患者，加用或换用维贝格隆：一项随机、平行组、多中心试验（） 。
BMJ Open. 2025 Mar 24;15(3):e094230. doi: 10.1136/bmjopen-2024-094230.
8
Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis.为特发性膀胱过度活动症选择最有效且安全的口服治疗方法：一项系统评价与网状Meta分析
Eur Urol Focus. 2022 Jul;8(4):1072-1089. doi: 10.1016/j.euf.2021.08.011. Epub 2021 Sep 22.
9
Clinically Meaningful Improvements With Vibegron in Men With Overactive Bladder and Benign Prostatic Hyperplasia: A Responder Analysis of the Phase 3 COURAGE Trial.
Urology. 2025 Sep 1. doi: 10.1016/j.urology.2025.08.051.
10
Comparison of Mirabegron and Vibegron in Women With Treatment-Naive Overactive Bladder: A Randomized Controlled Study.米拉贝隆与维贝隆治疗初治女性膀胱过度活动症的比较：一项随机对照研究。
Urology. 2023 May;175:67-73. doi: 10.1016/j.urology.2023.02.003. Epub 2023 Feb 22.

本文引用的文献

1
Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes.维贝格隆治疗膀胱过度活动症：疗效、安全性及患者报告结局的全面综述
World J Urol. 2025 Aug 26;43(1):514. doi: 10.1007/s00345-025-05799-8.
2
Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial.米拉贝隆与维贝隆治疗女性膀胱过度活动症的临床疗效和安全性比较：一项多中心前瞻性随机交叉试验。
World J Urol. 2024 Mar 2;42(1):113. doi: 10.1007/s00345-024-04799-4.
3
Comparison of Mirabegron and Vibegron in Women With Treatment-Naive Overactive Bladder: A Randomized Controlled Study.
米拉贝隆与维贝隆治疗初治女性膀胱过度活动症的比较：一项随机对照研究。
Urology. 2023 May;175:67-73. doi: 10.1016/j.urology.2023.02.003. Epub 2023 Feb 22.
4
Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study.米拉贝隆使用者与抗胆碱能药物治疗膀胱过度活动症使用者的心血管风险比较：一项非干预性、多国队列研究的结果。
Drug Saf. 2021 Aug;44(8):899-915. doi: 10.1007/s40264-021-01095-7. Epub 2021 Jul 8.
5
Mirabegron improves quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study.米拉贝隆可改善膀胱过度活动症患者的生活质量、治疗满意度及治疗依从性：一项多中心、非干预性、真实世界的12个月研究。
Curr Med Res Opin. 2018 May;34(5):785-793. doi: 10.1080/03007995.2017.1419170. Epub 2018 Jan 10.